Document is current
Any future updates will be listed below
-
Authors
Ke, Lu
Zhou, Jing
Mao, Wenjian
Chen, Tao
Zhu, Yin
Pan, Xinting
Mei, Hong
Singh, Vikesh
Buxbaum, James
Doig, Gordon
He, Chengjian
Gu, Weili
Lu, Weihua
Tu, Shumin
Ni, Haibin
Zhang, Guoxiu
Zhao, Xiangyang
Sun, Junli
Chen, Weiwei
Song, Jingchun
Shao, Min
Tu, Jianfeng
Xia, Liang
He, Wenhua
Zhu, Qingyun
Li, Kang
Yao, Hongyi
Wu, Jingyi
Fu, Long
Jiang, Wendi
Zhang, He
Lin, Jiajia
Li, Baiqiang
Tong, Zhihui
Windsor, John
Liu, Yuxiu
Li, Weiqin https://orcid.org/0000-0002-8807-6784
,
Ke, Lu
Zhou, Jing
Mao, Wenjian
Jiang, Wendi
Zhang, He
Lin, Jiajia
Huang, Mingfeng
Cao, Longxiang
Lu, Mengjie
Chen, Yan
Li, Gang
Ye, Bo
Li, Baiqiang
Tong, Zhihui
Liu, Yuxiu
Li, Weiqin
Chen, Tao
Shao, Fang
Lv, Nonghua
Zhu, Yin
Xia, Liang
He, Wenhua
Chen, Zhenping
Pan, Xinting
Zhu, Qingyun
Wan, Youdong
Mei, Hong
Li, Kang
Chen, Miao
He, Chengjian
Yao, Hongyi
Zhu, Zigui
Gu, Weili
Lu, Weihua
Wu, Jingyi
Zhou, Feng
Tu, Shumin
Fu, Long
Xue, Bing
Ni, Haibin
Huang, Xiaofei
Zhou, Dandan
Zhang, Guoxiu
Ren, Lening
Li, Dahuan
Zhao, Xiangyang
Zhao, Wei
Chen, Xiaomei
Sun, Junli
Xin, Keke
Chen, Weiwei
Xu, Qingcheng
Song, Jingchun
Zeng, Qingbo
Shao, Min
Zhao, Dongsheng
Tu, Jianfeng
Yang, Hongguo
Wu, Bin
Ye, Huaguang
Chen, Mingzhi
Chen, Yingjie
Yang, Mei
Gao, Hong
Li, Qiang
Zhao, Lijuan
Chen, Guobing
Li, Yafei
Xia, Honghai
Yang, Dongliang
Zhou, Shusheng
Lin, Jiyan
Liu, Siyao
Hong, Donghuang
Shi, Songjing
Wang, Zuozheng
Yao, Weijie
Sun, Yi
Qin, Kaixiu
Xu, Shan
Yu, Lei
Guo, Feng
Lin, Yongjun
Zhou, Yun
Jiao, Qinghai
Feng, Quanxing
Li, Zhiyong
-
Funding
Funding for this research was provided by:
SciClone Pharmaceuticals Holding Limited
Science and technology project of Jiangsu Province (SBE2016750187)
- License Information
-
More Information
Article History
Received: 26 January 2022
Accepted: 16 May 2022
First Online: 17 June 2022
Declarations
:
: WL reports consultancy fees and grants from SciClone Pharmaceuticals. ZT reports speaker fees from SciClone Pharmaceuticals. LK reports speaker fees from SciClone Pharmaceuticals. VS reports consultant fees and grants Abbvie, medical advisory board participant for Envara, and grants from Theraly and Orgenesis. The other authors have no relevant conflict of interest to declare.
: The protocol was prospectively approved by the human research ethics committee of all participating institutions and reported prior to completion of the study. This study was approved by the ethics committee of Jinling Hospital. The ethical approval document ID is 2015NZKY-004-02. Site ethical approvals were obtained from ethics committees of the participating sites before commencement of recruitment.
: Consent to participate was provided prospectively from all participants or their next of kin. The signed consent forms for all participants included consent to publication of aggregate data. The authors all consent to publication of the manuscript.
